Due to AI drones slamming this site, we have added IP blocking on excessive calls. Email us if you get blocked and send this [35.174.62 ]

🍽️ aprepitant,(prescription)

AI Engines For more Details: PerplexityKagi LabsYou

  1. Prevention of Chemotherapy-Induced Nausea and Vomiting (CINV): Aprepitant is effective in preventing both acute and delayed nausea and vomiting associated with highly emetogenic chemotherapy (chemotherapy that is likely to cause severe nausea and vomiting) as well as moderately emetogenic chemotherapy.

  2. Prevention of Postoperative Nausea and Vomiting (PONV): Aprepitant can also be used to prevent nausea and vomiting following surgery.

  3. NK1 Receptor Antagonist: Aprepitant works by blocking the action of substance P, a neurotransmitter involved in the vomiting reflex, at the neurokinin 1 (NK1) receptor in the brain.

  4. Multiple Dosage Forms: Aprepitant is available in oral (capsule) and intravenous (IV) formulations. The oral form is typically taken before chemotherapy or surgery, while the IV form may be administered in a healthcare setting.

  5. Three-Day Regimen: Aprepitant is often prescribed as part of a three-day regimen, with the first dose taken prior to chemotherapy or surgery, followed by additional doses on subsequent days to provide continued protection against nausea and vomiting.

  6. Combination Therapy: Aprepitant is frequently used in combination with other antiemetic medications, such as 5-HT3 receptor antagonists (e.g., ondansetron) and corticosteroids, to further enhance its antiemetic effects.

  7. Well-Tolerated: Aprepitant is generally well-tolerated, with common side effects including fatigue, dizziness, constipation, diarrhea, headache, and changes in taste perception.

  8. Drug Interactions: Aprepitant may interact with certain medications, particularly those metabolized by the cytochrome P450 enzyme system. It can increase the blood levels of drugs such as warfarin, dexamethasone, and hormonal contraceptives, potentially leading to an increased risk of side effects.

  9. Special Populations: Aprepitant should be used with caution in patients with liver impairment, as it is primarily metabolized by the liver. Dose adjustments may be necessary in these patients.

  10. Pregnancy and Lactation: The safety of aprepitant during pregnancy and breastfeeding has not been well-established. It should be used during pregnancy only if the potential benefits justify the potential risks to the fetus, and breastfeeding should be avoided during treatment.

;

Check for interactions on Supp.AI   |   πŸ“š PubMed Citations   |   βš—οΈ Compensation for antibiotic usage

Data Contradictions β€” Limits of Certainity

Impacted of aprepitant,(prescription) On Probiotics

Rank Probiotic Impact
species Akkermansia muciniphila Reduces
species Bifidobacterium adolescentis Reduces
species Bifidobacterium longum Reduces
species Escherichia coli Reduces
species Lacticaseibacillus paracasei Reduces
subspecies Bifidobacterium longum subsp. infantis Reduces
subspecies Bifidobacterium longum subsp. longum Reduces

Bacteria Impacted by aprepitant,(prescription)

We extend modifiers to include items that changes the parent and child taxa. I.e. for a species, that would be the genus that is belongs to and the strains in the species.

πŸ§™?

Taxonomy Rank Effect Citations Notation
Phocaeicola genus Decreases 👪 Source Study
Roseburia genus Decreases 👪 Source Study
Blautia genus Decreases 👪 Source Study
Veillonella genus Decreases 👪 Source Study
Segatella genus Decreases 👪 Source Study
Coprococcus genus Decreases 👪 Source Study
Odoribacter genus Decreases 👪 Source Study
Dorea genus Decreases 👪 Source Study
Collinsella genus Decreases 👪 Source Study proinflammatory
Clostridioides genus Decreases 👪 Source Study
Bacteroides genus Decreases 👪 Source Study
Parabacteroides genus Decreases 👪 Source Study BMI, fat percent,blood pressure
Bifidobacterium genus Decreases 👪 Source Study
Enterocloster genus Decreases 👪 Source Study
Mediterraneibacter genus Decreases 👪 Source Study
Ruminococcus genus Decreases 👪 Source Study
Clostridium genus Decreases 👪 Source Study Pathogen
Bilophila genus Decreases 👪 Source Study High Level Cause Brain Fog(Cognitive impairment)
Akkermansia genus Decreases 👪 Source Study
Agathobacter genus Decreases 👪 Source Study
Lacticaseibacillus genus Decreases 👪 Source Study
Escherichia genus Decreases 👪 Source Study
Streptococcus genus Decreases 👪 Source Study
Thomasclavelia genus Decreases 👪 Source Study
Lacrimispora genus Decreases 👪 Source Study
unclassified Robinsoniella no rank Decreases ⚗️ Source Study
unclassified Fusobacterium no rank Decreases ⚗️ Source Study
Escherichia coli O80:H26 no rank Decreases 👶 Source Study
Eggerthellales order Decreases ⚗️ Source Study
Escherichia coli O145 serogroup Decreases 👶 Source Study
Escherichia coli O157 serogroup Decreases 👶 Source Study
Escherichia coli O26 serogroup Decreases 👶 Source Study
Escherichia coli O43 serogroup Decreases 👶 Source Study
Escherichia coli O1:H42 serotype Decreases 👶 Source Study
Escherichia coli O104:H4 serotype Decreases 👶 Source Study
Escherichia coli O121:H19 serotype Decreases 👶 Source Study
Escherichia coli O127:H6 serotype Decreases 👶 Source Study
Escherichia coli O139:H28 serotype Decreases 👶 Source Study
Escherichia coli O157:H7 serotype Decreases 👶 Source Study bloody diarrhea
Escherichia coli O44:H18 serotype Decreases 👶 Source Study
Escherichia coli O55:H7 serotype Decreases 👶 Source Study
Escherichia coli O6:H16 serotype Decreases 👶 Source Study
Escherichia coli O7:K1 serotype Decreases 👶 Source Study
Phocaeicola vulgatus species Decreases 📓 Source Study
Bacteroides fragilis species Decreases 📓 Source Study H02076 Bacteroides infection
Roseburia intestinalis species Decreases 📓 Source Study
Roseburia hominis species Decreases 📓 Source Study
Blautia obeum species Decreases 📓 Source Study
Parabacteroides distasonis species Decreases 📓 Source Study
Bacteroides caccae species Decreases 📓 Source Study
Bifidobacterium longum species Decreases 📓 Source Study
Veillonella parvula species Decreases 📓 Source Study
Segatella copri species Decreases 📓 Source Study Over 70%ile Indicator of mycotoxin present
Coprococcus comes species Decreases 📓 Source Study
Odoribacter splanchnicus species Decreases 📓 Source Study
Bacteroides uniformis species Decreases 📓 Source Study Infectious bacteria
Dorea formicigenerans species Decreases 📓 Source Study
Bacteroides xylanisolvens species Decreases 📓 Source Study
Collinsella aerofaciens species Decreases 📓 Source Study
Clostridioides difficile species Decreases 📓 Source Study Colitis
[Ruminococcus] torques species Decreases 📓 Source Study
Bacteroides ovatus species Decreases 📓 Source Study
Enterocloster bolteae species Decreases 📓 Source Study
Ruminococcus bromii species Decreases 📓 Source Study
[Ruminococcus] gnavus species Decreases 📓 Source Study
Parabacteroides merdae species Decreases 📓 Source Study Infectious bacteria
Clostridium perfringens species Decreases 📓 Source Study Food poisoning, gas gangrene
Bifidobacterium adolescentis species Decreases 📓 Source Study
Bacteroides thetaiotaomicron species Decreases 📓 Source Study
Bilophila wadsworthia species Decreases 📓 Source Study
Akkermansia muciniphila species Decreases 📓 Source Study
Agathobacter rectalis species Decreases 📓 Source Study
Lacticaseibacillus paracasei species Decreases 📓 Source Study
Escherichia coli species Decreases 📓 Source Study Diarrheal disease in children and travelers, Foodborne diarrhea outbreaks, hemorrhagic colitis, hemolytic-uremic syndrome
Streptococcus parasanguinis species Decreases 📓 Source Study
Anaerofustis stercorihominis species Decreases ⚗️ Source Study
Asaccharospora irregularis species Decreases ⚗️ Source Study
Lactonifactor longoviformis species Decreases ⚗️ Source Study
Paraprevotella clara species Decreases ⚗️ Source Study
Slackia sp. NATTS species Decreases ⚗️ Source Study
Anaerosporobacter mobilis species Decreases ⚗️ Source Study
Pseudoflavonifractor capillosus species Decreases ⚗️ Source Study
[Collinsella] massiliensis species Decreases ⚗️ Source Study
Thomasclavelia ramosa species Decreases 📓 Source Study
Parvibacter caecicola species Decreases ⚗️ Source Study
Lacrimispora saccharolytica species Decreases 📓 Source Study
Coriobacterineae suborder Decreases ⚗️ Source Study
Bifidobacterium longum subsp. infantis subspecies Decreases 👶 Source Study
Bifidobacterium longum subsp. longum subspecies Decreases 👶 Source Study
Bifidobacterium longum subsp. suillum subspecies Decreases 👶 Source Study
Lacticaseibacillus paracasei subsp. paracasei subspecies Decreases 👶 Source Study
Chlamydiae/Verrucomicrobia group superphylum Decreases ⚗️ Source Study

Impact of aprepitant,(prescription) on Conditions from US National Library of Medicine

A higher number indicates impact on more bacteria associated with the condition and confidence on the impact.

We have X bacteria high and Y low reported. We find that the modifier reduces some and increases other of these two groups. We just tally: X|reduces + Y|Increase = Positive   X|increases + Y|decrease = Negative.

Benefit Ratio:
Numbers above 0 have increasing positive effect.
Numbers below 0 have increasing negative effect.

Condition Positive Impact Negative Impact Benefit Ratio Impact
Abdominal Aortic Aneurysm 0.2 0.2
Acne 0.4 -0.4
ADHD 6 0.5 11
Age-Related Macular Degeneration and Glaucoma 1 0.4 1.5
Allergic Rhinitis (Hay Fever) 2.1 2.1 0
Allergies 6 3.3 0.82
Allergy to milk products 1.4 1 0.4
Alopecia (Hair Loss) 2.4 2.4
Alzheimer's disease 3.8 7.6 -1
Amyotrophic lateral sclerosis (ALS) Motor Neuron 3.7 1.1 2.36
Ankylosing spondylitis 4.8 1.6 2
Anorexia Nervosa 0.4 2.4 -5
Antiphospholipid syndrome (APS) 1.9 0.2 8.5
Asthma 0.8 1.7 -1.13
Atherosclerosis 1.3 3.1 -1.38
Atrial fibrillation 4 2.6 0.54
Autism 12 10.8 0.11
Barrett esophagus cancer 0.5 0.1 4
benign prostatic hyperplasia 0.1 0.1
Bipolar Disorder 1.6 1.9 -0.19
Brain Trauma 0.9 0.9 0
Carcinoma 4.1 3.6 0.14
Celiac Disease 2.8 5.1 -0.82
Cerebral Palsy 1.6 1.8 -0.13
Chronic Fatigue Syndrome 6 9.1 -0.52
Chronic Kidney Disease 2.6 1.9 0.37
Chronic Lyme 0.9 -0.9
Chronic Obstructive Pulmonary Disease (COPD) 0.8 1 -0.25
Chronic Urticaria (Hives) 1.3 2.5 -0.92
Coagulation / Micro clot triggering bacteria 0.9 1.5 -0.67
Colorectal Cancer 4 1.1 2.64
Constipation 1.6 1 0.6
Coronary artery disease 1.8 1.5 0.2
COVID-19 12.2 16.1 -0.32
Crohn's Disease 9 6.3 0.43
cystic fibrosis 0.3 1.4 -3.67
deep vein thrombosis 0.3 1 -2.33
Depression 11 10.1 0.09
Dermatomyositis 0.1 0.4 -3
Eczema 1.4 1.9 -0.36
Endometriosis 3.2 1.4 1.29
Eosinophilic Esophagitis 0.5 -0.5
Epilepsy 3.3 3.3 0
Fibromyalgia 3.1 4.2 -0.35
Functional constipation / chronic idiopathic constipation 7.2 6.1 0.18
gallstone disease (gsd) 2.8 0.9 2.11
Gastroesophageal reflux disease (Gerd) including Barrett's esophagus 2.5 1.1 1.27
Generalized anxiety disorder 1.6 2.7 -0.69
giant cell arteritis 0.4 -0.4
Glioblastoma 0.1 -0.1
Gout 0.5 -0.5
Graves' disease 1.7 1.9 -0.12
Halitosis 0.9 0.1 8
Hashimoto's thyroiditis 3.5 1.1 2.18
Hidradenitis Suppurativa 0.4 0.5 -0.25
Histamine Issues,Mast Cell Issue, DAO Insufficiency 3.6 1.1 2.27
hypercholesterolemia (High Cholesterol) 0.9 0.5 0.8
hyperglycemia 0.1 2.5 -24
Hyperlipidemia (High Blood Fats) 1.1 0.5 1.2
hypersomnia 0.7 -0.7
hypertension (High Blood Pressure 2.6 6.7 -1.58
Hypothyroidism 1.4 -1.4
Hypoxia 1.1 1.1
IgA nephropathy (IgAN) 4.9 -4.9
Inflammatory Bowel Disease 3.6 11.2 -2.11
Insomnia 1.1 0.9 0.22
Intelligence 1.8 1 0.8
Intracranial aneurysms 1.8 0.5 2.6
Irritable Bowel Syndrome 5 5.6 -0.12
Liver Cirrhosis 5.7 4.2 0.36
Long COVID 9.2 10 -0.09
Low bone mineral density 1 -1
Lung Cancer 1.1 1.9 -0.73
ME/CFS with IBS 1.3 3.8 -1.92
ME/CFS without IBS 1.4 3.3 -1.36
Menopause 2.5 2.5
Metabolic Syndrome 9.6 11.6 -0.21
Mood Disorders 14.8 10.1 0.47
multiple chemical sensitivity [MCS] 0.8 0.5 0.6
Multiple Sclerosis 4.5 6.4 -0.42
Multiple system atrophy (MSA) 1.9 1.3 0.46
Neuropathy (all types) 0.9 0.1 8
neuropsychiatric disorders (PANDAS, PANS) 0.7 0.7
Nonalcoholic Fatty Liver Disease (nafld) Nonalcoholic 3 6.3 -1.1
NonCeliac Gluten Sensitivity 0.4 -0.4
Obesity 11.7 5.2 1.25
obsessive-compulsive disorder 8.3 6.1 0.36
Osteoarthritis 1.9 0.4 3.75
Osteoporosis 1.8 1.4 0.29
pancreatic cancer 0.6 0.6
Parkinson's Disease 3.1 4.8 -0.55
Polycystic ovary syndrome 3.3 2.8 0.18
Postural orthostatic tachycardia syndrome 0.4 0.9 -1.25
Premenstrual dysphoric disorder 1.4 0.4 2.5
primary biliary cholangitis 0.5 1.4 -1.8
Psoriasis 5.6 4.3 0.3
rheumatoid arthritis (RA),Spondyloarthritis (SpA) 7.5 5.1 0.47
Rosacea 1.7 0.9 0.89
Schizophrenia 8.6 2.7 2.19
scoliosis 0.5 0.6 -0.2
Sjögren syndrome 4.1 4.2 -0.02
Sleep Apnea 1.8 1.9 -0.06
Small Intestinal Bacterial Overgrowth (SIBO) 0.3 1 -2.33
Stress / posttraumatic stress disorder 3.1 2.8 0.11
Systemic Lupus Erythematosus 5.1 2.3 1.22
Tic Disorder 1.9 2.3 -0.21
Tourette syndrome 0.2 0.4 -1
Type 1 Diabetes 5.5 2.7 1.04
Type 2 Diabetes 10.2 8.9 0.15
Ulcerative colitis 2.8 7.9 -1.82
Unhealthy Ageing 7.1 2.6 1.73

This is an Academic site. It generates theoretical models of what may benefit a specific microbiome results.

Explanations/Info/Descriptions are influenced by Large Language Models and may not be accurate and include some hallucinations. Please report any to us for correction.

Copyright 2016-2024 Lassesen Consulting, LLC [2007], DBA, Microbiome Prescription. All rights served.
Permission to data scrap or reverse engineer is explicitly denied to all users. U.S. Code Title 18 PART I CHAPTER 47 Β§β€―1030, CETS No.185, CFAA
Use of data on this site is prohibited except under written license. There is no charge for individual personal use. Use for any commercial applications or research requires a written license.
Caveat emptor: Analysis and suggestions are based on modelling (and thus infererence) based on studies. The data sources are usually given for those that wish to consider alternative inferences. theories and models.
Inventions/Methodologies on this site are Patent Pending.

Microbiome Prescription do not make any representations that data or analyses available on this site is suitable for human diagnostic purposes, for informing treatment decisions, or for any other purposes and accept no responsibility or liability whatsoever for such use.
This site is not Health Insurance Portability and Accountability Act of 1996 (HIPAA) compliant. [35.174.62 ]